{"id":3309,"date":"2023-02-09T19:33:34","date_gmt":"2023-02-09T10:33:34","guid":{"rendered":"https:\/\/www.asahikawa-med.ac.jp\/hospital\/pharmacy\/?page_id=3309"},"modified":"2025-01-24T11:39:00","modified_gmt":"2025-01-24T02:39:00","slug":"1998%e5%b9%b4%ef%bd%9e2009%e5%b9%b4-%e6%a5%ad%e7%b8%be","status":"publish","type":"page","link":"https:\/\/www.asahikawa-med.ac.jp\/hospital\/pharmacy\/1998%e5%b9%b4%ef%bd%9e2009%e5%b9%b4-%e6%a5%ad%e7%b8%be","title":{"rendered":"1998\u5e74\uff5e2012\u5e74 \u696d\u7e3e"},"content":{"rendered":"

\"\"<\/p>\n

\u539f\u8457\u8ad6\u6587(1998\u5e74~2012\u5e74)\u3000\u3000\u25bc<\/span><\/h3>\n
\n

2012\u5e74 \u539f\u8457\u8ad6\u6587<\/h4>\n
\n

1. \u5c71\u672c\u8b72, \u7c9f\u5c4b\u654f\u96c4, \u5c0f\u57ce\u9999\u7dd2\u91cc, \u68ee\u7530\u771f\u6a39\u5b50, \u5ddd\u5b88\u7530\u65e9\u7d00, \u795e\u5d0e\u90c1\u4ee3, \u5c0f\u5ddd\u8061, \u677f\u57a3\u7950\u4e00, \u5927\u6edd\u5eb7\u4e00, \u5c71\u672c\u4e45\u4ec1\u5b50, \u7530\u5d0e\u5609\u4e00, \u677e\u539f\u548c\u592b. \u85ac\u5264\u5e2b\u306b\u3088\u308b\u9ebb\u9154\u79d1\u533b\u652f\u63f4\u696d\u52d9-\u624b\u8853\u5ba4\u306b\u304a\u3051\u308b\u85ac\u5264\u65bd\u7528\u6e96\u5099-, \u533b\u7642\u85ac\u5b66 38(1), 34-42, 2012.<\/p>\n

 <\/p>\n

2. Tasaki Y, Yamamoto J, Omura T, Sakaguchi T, Kimura N, Ohtaki K, Ono T, Suno M, Asari M, Ohkubo T, Noda T, Awaya T, Shimizu K, Matsubara K. Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson\u2019s disease model, Neurosci Lett 521(1), 15-19, 2012.<\/p>\n

 <\/p>\n

3. Kono T, Satomi M, Suno M, Kimura N, Yamazaki H, Furukawa H, Matsubara K. Oxaliplatin-induced neurotoxicity involves TRPM8 in the mechanism of acute hypersensitivity to cold sensation. Brain Behav 2(1), 68-73, 2012.<\/p>\n

 <\/p>\n

4. Matsubara K, Asari M, Suno M, Awaya T, Sugawara M, Omura T, Yamamoto J, Maseda C, Tasaki Y, Shiono H, Shimizu K. Estimation of the duration after methamphetamine injection using a pharmacokinetic model in suspects who caused fatal traffic accidents. Leg Med 14, 191-196, 2012.<\/p>\n

 <\/p>\n

5. Tasaki Y, Yamamoto J, Omura T, Noda T, Kamiyama N, Yoshida K, Satomi M, Sakaguchi T, Asari M, Ohkubo T, Shimizu K, Matsubara K. Oxicam structure in non-steroidal anti-inflammatory drugs is essential to exhibit Akt-mediated neuroprotection against 1-methyl-4-phenyl pyridinium-induced cytotoxicity. Eur J Pharmacol 676, 57-63, 2012.<\/p>\n

 <\/p>\n

6. Omura T, Asari M, Yamamoto J, Kamiyama N, Oka K, Hoshina C, Maseda C, Awaya T, Tasaki Y, Shiono H, Shimizu K, Matsubara K. HRD1 levels increased by zonisamide prevented cell death and caspase-3 activation caused by endoplasmic reticulum stress in SH-SY5Y cells. J Mol Neurosci 46, 527-535, 2012.<\/p>\n

 <\/p>\n

7. Asari M, Omura T, Oka K, Maseda C, Tasaki Y, Shiono H, Matsubara K, Matsuda M, Shimizu K. Multiplex PCR-based Alu insertion polymorphisms genotyping for identifying individuals of Japanese ethnicity. Genomics 99, 227-232, 2012.<\/p><\/div>\n

2011\u5e74 \u539f\u8457\u8ad6\u6587<\/h4>\n
\n

1. \u7c9f\u5c4b\u654f\u96c4, \u677e\u539f\u548c\u592b, \u6728\u6751\u5468\u53e4, \u68ee\u7530\u771f\u6a39\u5b50, \u5c71\u4e0b\u606d\u7bc4, \u5927\u6edd\u5eb7\u4e00, \u98ef\u7530\u614e\u4e5f, \u5c0f\u679d\u6b63\u5409, \u539f\u5343\u6075\u5b50, \u5c71\u672c\u4e45\u4ec1\u5b50, \u4e09\u597d\u654f\u4e4b, \u7530\u5d0e\u5609\u4e00, \u9577\u8c37\u90e8\u76f4\u5e78. \u85ac\u5264\u5e2b\u306b\u3088\u308b\u7591\u7fa9\u7167\u4f1a\u5f8c\u306e\u51e6\u65b9\u5909\u66f4\u304a\u3088\u3073Do\u51e6\u65b9\u306e\u5165\u529b\u30d7\u30ed\u30c8\u30b3\u30eb \u2015\u533b\u653f\u5c40\u9577\u901a\u77e5\u300c\u533b\u7642\u30b9\u30bf\u30c3\u30d5\u306e\u5354\u50cd\u30fb\u9023\u643a\u306b\u3088\u308b\u30c1\u30fc\u30e0\u533b\u7642\u306e\u63a8\u9032\u306b\u3064\u3044\u3066\u300d\u306e\u5177\u4f53\u5316. \u65e5\u672c\u75c5\u9662\u85ac\u5264\u5e2b\u4f1a\u96d1\u8a8c 47(12), 1575-1579, 2012.<\/p>\n

 <\/p>\n

2. \u5c0f\u91ce\u5c1a\u5fd7, \u7c9f\u5c4b\u654f\u96c4, \u90fd\u7bc9\u4ec1\u7f8e, \u9808\u91ce\u5b66, \u5c71\u4e0b\u606d\u7bc4, \u5927\u6edd\u5eb7\u4e00, \u7530\u5d0e\u5609\u4e00, \u677e\u539f\u548c\u592b. \u591a\u898f\u683c\u304c\u4f75\u58f2\u3055\u308c\u3066\u3044\u308b\u6ce8\u5c04\u7528\u6297\u304c\u3093\u5264\u306e\u6700\u9069\u306a\u63a1\u7528\u6226\u7565\u306b\u95a2\u3059\u308b\u7814\u7a76. \u533b\u7642\u85ac\u5b66 37(8), 467-474, 2011.<\/p>\n

 <\/p>\n

3. \u677e\u539f\u548c\u592b, \u5916\u5c71\u8061, \u4f50\u85e4\u535a, \u9234\u6728\u6d0b\u53f2, \u7c9f\u5c4b\u654f\u96c4, \u7530\u5d0e\u5609\u4e00, \u5b89\u5ca1\u4fca\u660e, \u5800\u5185\u9f8d\u4e5f. \u85ac\u5264\u5e2b\u306e\u75c5\u68df\u52e4\u52d9\u6642\u9593\u304c\u9577\u3044\u307b\u3069\u85ac\u5264\u304c\u95a2\u9023\u3059\u308b\u30a4\u30f3\u30b7\u30c7\u30f3\u30c8\u767a\u751f\u6570\u306f\u5c11\u306a\u3044 \u56fd\u7acb\u5927\u5b66\u75c5\u9662\u306b\u304a\u3051\u308b\u8abf\u67fb. \u85ac\u5b66\u96d1\u8a8c 131(4), 635-641, 2011.<\/p>\n

 <\/p>\n

4. \u65e9\u52e2\u4f38\u6b63, \u5ca9\u5c71\u8a13\u5178, \u5927\u6edd\u5eb7\u4e00, \u5c71\u4e0b\u606d\u7bc4, \u7c9f\u5c4b\u654f\u96c4, \u677e\u539f\u548c\u592b. \u30aa\u30d6\u30e9\u30fc\u30c8\u3042\u308b\u3044\u306f\u670d\u85ac\u88dc\u52a9\u30bc\u30ea\u30fc\u3067\u5305\u3093\u3060\u9320\u5264\u53ca\u3073\u30ab\u30d7\u30bb\u30eb\u5264\u306b\u304a\u3051\u308b \u6eb6\u51fa\u6319\u52d5. \u85ac\u5b66\u96d1\u8a8c 131(1), 161-168, 2011.<\/p>\n

 <\/p><\/div>\n

2010\u5e74 \u539f\u8457\u8ad6\u6587<\/h4>\n
\n1. \u5927\u6edd\u5eb7\u4e00\uff0c\u9ebb\u4e0b\u667a\u52a0\uff0c\u7db1\u5ddd\u667a\u4e4b\uff0c\u5c71\u672c\u8b72\uff0c\u5c0f\u57ce\u9999\u7dd2\u91cc\uff0c\u4e09\u597d\u654f\u4e4b\uff0c\u7530\u5d0e\u5609\u4e00\uff0c\u7c9f\u5c4b\u654f\u96c4\uff0c\u677e\u539f\u548c\u592b\uff0e \u5f8c\u767a\u533b\u85ac\u54c1\u4f7f\u7528\u4fc3\u9032\u306b\u304a\u3051\u308b\u554f\u984c\u70b9\u3000\u2212\u3000\u300c\u5f8c\u767a\u533b\u85ac\u54c1\u3078\u306e\u5909\u66f4\u4e0d\u53ef\u300d\u51e6\u65b9\u305b\u3093\u306e\u5b9f\u614b\u3068\u60a3\u8005\u610f\u8b58\u306e\u8abf\u67fb J \u65e5\u672c\u75c5\u9662\u85ac\u5264\u5e2b\u4f1a\u96d1\u8a8c<\/i>, 46(2)\uff1a209-213, 2010.<\/p>\n

 <\/p>\n

2. \u677e\u6751\u4e45\u7537\uff0c\u7531\u4e95\u5247\u4e4b\uff0c\u5ca9\u5c71\u8a13\u5178\uff0c\u65e9\u52e2\u4f38\u6b63\uff0c\u5927\u6edd\u5eb7\u4e00\uff0c\u5c71\u4e0b\u606d\u7bc4\uff0c\u7c9f\u5c4b\u654f\u96c4\uff0c\u85e4\u6ca2\u82b3\u5247\uff0c\u677e\u91ce\u548c\u5f66\uff0c\u677e\u539f\u548c\u592b\uff0e \u30c8\u30ea\u30a2\u30be\u30e9\u30e0\u9320\u306e\u6eb6\u51fa\u6027\u306b\u53ca\u307c\u3059pH\u304a\u3088\u3073\u30a2\u30eb\u30b3\u30fc\u30eb\u306e\u5f71\u97ff\uff0d\u5148\u767a\u533b\u85ac\u54c1\u3068\u5f8c\u767a\u533b\u85ac\u54c1\u306e\u6bd4\u8f03\u691c\u8a0e\uff0d Progress in Medicine, 30(4)\uff1a1157-1163, 2010.<\/p>\n

 <\/p>\n

3. \u9ebb\u4e0b\u667a\u52a0\uff0c\u7530\u5d0e\u5609\u4e00\uff0c\u5927\u6751\u53cb\u535a\uff0c\u98ef\u7530\u614e\u4e5f\uff0c\u5c71\u672c\u8b72\uff0c\u90fd\u7bc9\u4ec1\u7f8e\uff0c\u4e95\u4e0a\u6b63\u671d\uff0c\u5927\u6edd\u5eb7\u4e00\uff0c\u7c9f\u5c4b\u654f\u96c4\uff0c\u4e09\u597d\u654f\u4e4b\uff0c\u9593\u702c\u7530\u5343\u9999\u6681\uff0c\u6e05\u6c34\u60e0\u5b50\uff0c\u677e\u539f\u548c\u592b\uff0e \u6551\u6025\u533b\u7642\u306b\u304a\u3051\u308b\u6feb\u7528\u85ac\u7269\u30b9\u30af\u30ea\u30fc\u30cb\u30f3\u30b0\u3068\u8840\u4e2d\u30a2\u30eb\u30b3\u30fc\u30eb\u6fc3\u5ea6\u6e2c\u5b9a\uff0d\u5b9f\u52d9\u5b9f\u7fd2\u30e2\u30c7\u30eb\u30fb\u30b3\u30a2\u30ab\u30ea\u30ad\u30e5\u30e9\u30e0\u300c\u4e2d\u6bd2\u533b\u7642\u3078\u306e\u8ca2\u732e\u300d\u3078\u306e\u5bfe\u5fdc\uff0d \u533b\u7642\u85ac\u5b66, 36(8)\uff1a575-579, 2010.<\/p>\n

 <\/p>\n

4. Tasaki Y, Omura T, Yamada T, Ohkubo T, Suno M, Iida S, Sakaguchi T, Asari M, Shimizu K, Matsubara K. Meloxicam protects cell damage from 1-methyl-4-phenyl pyridinium toxicity via the phosphatidylinositol 3-kinase\/Akt pathway in human dopaminergic neuroblastoma SH-SY5Y cells. Brain Res., 1344: 25-33, 2010.<\/p>\n

 <\/p>\n

5. Toru Kono, Machiko Satomi, Toshiyuki Asama, Yoshiaki Ebisawa, Naoyuki Chisato, Manabu Suno, Hidenori Karasaki, Hiroyuki Furukawa, Kazuo Matsubara. Cetuximab-induced hypomagnesaemia aggravates peripheral sensory neurotoxicity caused by oxaliplatin. J Gastrointestinal Oncology, 1(2):97-101, 2010.<\/p>\n

 <\/p>\n

6. Asari M, Omura T, Maseda C, Shiono H, Tasaki Y, Matsubara K, Shimizu K. Enhanced discrimination of single nucleotide polymorphisms using 3′ nucleotide differences in ligase detection reaction probes. Mol Cell Probes., 24(6):381-386, 2010.<\/p>\n

 <\/p>\n

7. Asari M, Omura T, Maseda C, Matsubara K, Shiono H, Shimizu K.. A new method for human ABO genotyping using a universal reporter primer system. Eur J Pharmacol., 676(1-3):57-63, 2010.<\/p>\n

 <\/p><\/div>\n

2009\u5e74 \u539f\u8457\u8ad6\u6587<\/h4>\n
\n1. Asari M, Omura, T, Maseda, C, Matsubara K, Shiono H, Shimizu K. A new method for human ABO genotyping using a universal reporter primer system. J Forensic Sci<\/i>, 55(6):1576-1581, 2010.<\/p>\n

 <\/p>\n

2. Noda T, Yamada T, Ohkubo T, Omura T, Ono T, Adachi T, Awaya T, Tasaki Y, Shimizu K, Matsubara K. Hot-Water Extracts of Polygonum Multiflorum Do Not Induce Any Toxicity but Elicit Limited Beneficial Effects on the Liver in Mice. J Health Sci 55, 720-725, 2009.<\/p>\n

 <\/p>\n

3. Suno M, Kunisawa T, Yamagishi A, Ono T, Yamamoto J, Yamada T, Tasaki Y, Shimizu K, Iwasaki H, Matsubara K. Detection of landiolol using high-performance liquid chromatography\/fluorescence: a blood esterase-sensitive ultra-short-acting beta(1)-receptor antagonist. Chromatogr B, 877, 1705-8, 2009.<\/p>\n

 <\/p>\n

4. \u91cc\u898b\u771e\u77e5\u5b50, \u6cb3\u91ce\u900f, \u9593\u5bae\u898f\u7ae0, \u5343\u91cc\u76f4\u4e4b, \u6d77\u8001\u6fa4\u826f\u662d, \u83c5\u539f\u7766, \u6589\u85e4\u5b5d\u6210, \u677e\u539f\u548c\u592b, \u845b\u897f\u771e\u4e00. \u9032\u884c\u6027\u5927\u8178\u764c\u60a3\u8005\u3078\u611f\u899a\u6027\u795e\u7d4c\u969c\u5bb3\u7528\u90e8\u4f4d\u5225\u554f\u8a3a\u7968\u3092\u7528\u3044\u305fOxaliplatin\u306e\u672b\u68a2\u795e\u7d4c\u6bd2\u6027\u767a\u73fe\u306e\u691c\u8a0e. \u764c\u3068\u5316\u5b66\u7642\u6cd5 36, 1321-1325, 2009.<\/p>\n

 <\/p>\n

5. \u7c9f\u5c4b\u654f\u96c4, \u9577\u8c37\u90e8\u76f4\u5e78, \u68b6\u91ce\u6d69\u6a39, \u77f3\u8c37\u9ebb\u91cc\u5b50, \u5c71\u7530\u6b66\u5b8f, \u5c0f\u91ce\u5c1a\u5fd7, \u5927\u6edd\u5eb7\u4e00, \u5c71\u4e0b\u606d\u7bc4, \u4e09\u597d\u654f\u4e4b, \u7530\u5d0e\u5609\u4e00, \u677e\u539f\u548c\u592b. \u51e6\u65b9\u5165\u529b\u6642\u306e\u4f53\u8868\u9762\u7a4d\u3092\u30d9\u30fc\u30b9\u3068\u3057\u305f\u6ce8\u5c04\u85ac\u30aa\u30fc\u30c0\u4e0a\u9650\u91cf\u8b66\u544a\u30b7\u30b9\u30c6\u30e0. \u533b\u7642\u85ac\u5b66 35, 615-621, 2009.<\/p>\n

 <\/p>\n

6. \u7531\u4e95\u5247\u4e4b, \u677e\u6751\u4e45\u7537, \u65e9\u52e2\u4f38\u6b63, \u5927\u6edd\u5eb7\u4e00, \u539f\u5343\u6075\u5b50, \u7c9f\u5c4b\u654f\u96c4, \u677e\u91ce\u81f3\u6d0b, \u85e4\u6ca2\u82b3\u5247, \u677e\u539f\u548c\u592b. \u30c8\u30ea\u30a2\u30be\u30e9\u30e00.25mg\u9320\u306e\u534a\u5206\u5272\u9320\u3068\u30c8\u30ea\u30a2\u30be\u30e9\u30e00.125mg\u9320\u306b\u304a\u3051\u308b\u6eb6\u51fa\u6319\u52d5\u306e\u9055\u3044. Progress in Medicine 29, 3061-3066, 2009.<\/p>\n

 <\/p>\n

7. \u6e05\u6c34\u60e0\u5b50, \u4f50\u3005\u6728\u826f, \u89d2\u7530\u5eb7\u592b, \u5c0f\u6cc9\u535a\u4e00, \u6d45\u5229\u512a, \u5927\u6751\u53cb\u535a, \u9593\u702c\u7530\u5343\u9999\u6681, \u677e\u539f\u548c\u592b, \u5869\u91ce\u5bdb. \u6cd5\u533b\u5b66\u306e\u65b0\u3057\u3044\u793e\u4f1a\u8ca2\u732e \u65ed\u5ddd\u5e02\u9ad8\u9f62\u8005\u5b64\u7acb\u6b7b\u9632\u6b62\u30ac\u30a4\u30c9\u4f5c\u6210\u3078\u306e\u53d6\u308a\u7d44\u307f. \u6cd5\u533b\u5b66\u306e\u5b9f\u969b\u3068\u7814\u7a76 52, 221-226, 2009.<\/p>\n

 <\/p><\/div>\n

2008\u5e74 \u539f\u8457\u8ad6\u6587<\/h4>\n
\n

1.Asari M, Watanabe S, Matsubara K, Shiono H, Shimizu K. Single nucleotide polymorphism genotyping by mini-primer allele-specific amplification with universal reporter primers for identification of degraded DNA. Anal Biochem 386, 85-90, 2008.<\/p>\n

 <\/p>\n

2. Watanabe S, Terazawa K, Asari M, Matsubara K, Shiono H, Shimizu K. An autopsy case of sudden death due to acute gastric dilatation without rupture. Forensic Sci Int 18 180, 6-10, 2008.<\/p>\n

 <\/p>\n

3. \u5927\u7af9\u5b5d\u660e, \u85e4\u672c\u4f73\u7bc4, \u963f\u90e8\u771f\u7f8e, \u4e09\u597d\u8302\u6a39, \u9234\u6728\u5eb7\u79cb, \u5927\u5e73\u8cc0\u5b50, \u677e\u539f\u548c\u592b, \u9ad8\u5f8c\u88d5. \u6162\u6027\u809d\u708e\u60a3\u8005\u306b\u304a\u3051\u308b\u30b0\u30ea\u30c1\u30eb\u30ea\u30c1\u30f3\u88fd\u5264\u6295\u4e0e\u306b\u3088\u308b\u81e8\u5e8a\u52b9\u679c\u306e\u6bd4\u8f03. Progress in Medicine 28, 1787-1788, 2008.<\/p>\n

 <\/p>\n

4. \u5c71\u7530\u6b66\u5b8f, \u6885\u6d25\u5178\u5b50, \u5927\u6edd\u5eb7\u4e00, \u7db1\u5ddd\u667a\u4e4b, \u4f50\u85e4\u771f\u7531\u7f8e, \u5c0f\u57ce\u9999\u7dd2\u91cc, \u5c0f\u91ce\u5c1a\u5fd7, \u9808\u91ce\u5b66, \u98ef\u7530\u614e\u4e5f, \u5c71\u4e0b\u606d\u7bc4, \u7c9f\u5c4b\u654f\u96c4, \u7530\u5d0e\u5609\u4e00, \u677e\u539f\u548c\u592b. \u51e6\u65b9\u30aa\u30fc\u30c0\u30ea\u30f3\u30b0\u30b7\u30b9\u30c6\u30e0\u304a\u3088\u3073TDM\u30aa\u30fc\u30c0\u30ea\u30f3\u30b0\u30b7\u30b9\u30c6\u30e0\u3068\u9023\u52d5\u3057\u305f\u6297MRSA\u85ac\u4f7f\u7528\u5c4a\u3051\u51fa\u30b7\u30b9\u30c6\u30e0\u306f\u9069\u6b63\u4f7f\u7528\u3092\u63a8\u9032\u3059\u308b. \u533b\u7642\u85ac\u5b66 34, 419-425, 2008.<\/p>\n

 <\/p>\n

5. \u5c0f\u91ce\u5c1a\u5fd7, \u677e\u539f\u548c\u592b. \u5438\u5165\u7642\u6cd5 \u6c17\u7ba1\u652f\u5598\u606f\u30fbCOPD \u5438\u5165\u65b9\u6cd5\u3067\u77e5\u308a\u305f\u3044\u3053\u3068. \u85ac\u5c40 6, 2377-2380, 2008.<\/p>\n

 <\/p>\n

6. \u6e05\u6c34\u60e0\u5b50, \u6d45\u5229\u512a, \u6e21\u908a\u667a, \u5869\u91ce\u5bdb, \u677e\u539f\u548c\u592b, \u6885\u6d25\u5178\u5b50, \u5bcc\u7530\u6b63\u6587. \u30d1\u30e9\u30b3\u30fc\u30c8\u306e\u80ba\u6bd2\u6027\u6a5f\u69cb\u306b\u95a2\u3059\u308b\u691c\u8a0e. \u65e5\u672c\u6cd5\u533b\u5b66\u96d1\u8a8c 62, 78, 2008.<\/p>\n

 <\/p>\n

7. \u5927\u6edd\u5eb7\u4e00, \u6885\u6d25\u5178\u5b50, \u9ebb\u4e0b\u667a\u52a0, \u4e03\u7530\u77e5\u7f8e, \u90fd\u7bc9\u4ec1\u7f8e, \u77f3\u5ddd\u7965\u5b50, \u5b89\u9054\u77e5\u8f1d, \u4e95\u4e0a\u6b63\u671d, \u5c0f\u91ce\u5c1a\u5fd7, \u5c71\u7530\u6b66\u5b8f, \u7c9f\u5c4b\u654f\u96c4, \u5c0f\u5ddd\u8061, \u91cc\u898b\u771f\u77e5\u5b50, \u91ce\u7530\u654f\u5b8f, \u7530\u5d0e\u5609\u4e00, \u677f\u57a3\u7950\u4e00, \u516b\u6728\u771f\u7802\u5b50, \u7530\u5c3e\u597d\u6b63, \u7b20\u539f\u76f4\u90a6, \u85e4\u6ca2\u82b3\u5247, \u677e\u91ce\u548c\u5f66, \u677e\u539f\u548c\u592b. \u85ac\u9023\u643a:\u75c5\u9662\u85ac\u5264\u5e2b\u304c\u4ecb\u5728\u3059\u308b\u4fdd\u967a\u8abf\u5264\u85ac\u5c40\u304b\u3089\u306e\u30c8\u30ec\u30fc\u30b7\u30f3\u30b0\u30ec\u30dd\u30fc\u30c8\u30b7\u30b9\u30c6\u30e0\u306b\u3088\u308b\u85ac\u7269\u7642\u6cd5\u306e\u6709\u52b9\u6027\u30fb\u5b89\u5168\u6027\u3078\u306e\u5bc4\u4e0e. \u533b\u85ac\u30b8\u30e3\u30fc\u30ca\u30eb 44, 158-164, 2008.<\/p>\n

 <\/p>\n

8. \u6e21\u908a\u667a, \u6d45\u5229\u512a, \u4e39\u7950\u590f, \u677e\u539f\u548c\u592b, \u5869\u91ce\u5bdb, \u6e05\u6c34\u60e0\u5b50. \u30d0\u30b9\u30ad\u30e5\u30e9\u30fc\u30a2\u30af\u30bb\u30b9\u304c\u6b7b\u56e0\u306b\u95a2\u4e0e\u3057\u305f\u900f\u6790\u60a3\u8005\u306e4\u5256\u691c\u4f8b. \u6cd5\u533b\u5b66\u306e\u5b9f\u969b\u3068\u7814\u7a76 51, 225-232, 2008.<\/p>\n

 <\/p><\/div>\n

2007\u5e74 \u539f\u8457\u8ad6\u6587<\/h4>\n
\n

1. Kaneko M, Yasui S, Niinuma Y, Arai K, Omura T, Okuma Y, Nomura Y. A different pathway in the endoplasmic reticulum stress-induced expression of human HRD1 and SEL1 genes. FEBS Lett 581, 5355-60, 2007.<\/p>\n

 <\/p>\n

2. Suno M, Ono T, Iida S, Umetsu N, Ohtaki K, Yamada T, Awaya T, Satomi M, Tasaki Y, Shimizu K. Matsubara K. Improved HPCL detection of paclitaxel in patient\u2019s plasma using solid phase extraction, and semi-micro bore C18 separation and UV detection. J Chromatogr 860, 141-4, 2007.<\/p>\n

 <\/p>\n

3. \u5c0f\u91ce\u5c1a\u5fd7, \u5343\u8449\u85ab, \u9808\u91ce\u5b66, \u5c71\u4e0b\u606d\u7bc4, \u5c0f\u679d\u6b63\u5409, \u5c71\u7530\u6b66\u5b8f, \u5927\u6edd\u5eb7\u4e00, \u7c9f\u5c4b\u654f\u96c4, \u539f\u5343\u6075\u5b50, \u9ad8\u6a4b\u8ce2\u5c1a, \u4e09\u597d\u654f\u4e4b, \u5c0f\u5ddd\u8061, \u677f\u57a3\u7950\u4e00, \u7530\u5d0e\u5609\u4e00, \u677e\u539f\u548c\u592b. \u30a2\u30ec\u30cb\u30a6\u30b9\u5f0f\u3092\u7528\u3044\u305f\u6297\u764c\u5264\u8abf\u88fd\u5f8c\u306e\u5b89\u5b9a\u4e88\u6e2c. \u533b\u7642\u85ac\u5b66 33, 479-487, 2007.<\/p>\n

 <\/p>\n

4. \u7c9f\u5c4b\u654f\u96c4, \u85e4\u4e38\u30b5\u30e4\u30ab, \u6885\u6d25\u5178\u5b50, \u5229\u5ca1\u679c\u7f8e, \u5c0f\u57ce\u9999\u7dd2\u91cc, \u5c0f\u6797\u674f\u5948, \u68ee\u7530\u771f\u7531\u7f8e, \u6734\u7d18\u6176, \u77f3\u738b\u5fdc\u77e5, \u5c71\u4e0b\u606d\u7bc4, \u5c71\u672c\u4e45\u4ec1\u5b50, \u7530\u5d0e\u5609\u4e00, \u677e\u539f\u548c\u592b. \u500b\u3005\u306e\u60a3\u8005\u306b\u9069\u5fdc\u3057\u305f\u51e6\u65b9\u76e3\u67fb \uff0d\u75c5\u9662\u60c5\u5831\u30b7\u30b9\u30c6\u30e0\u304b\u3089\u306e\u60a3\u8005\u57fa\u672c\u60c5\u5831\u306e\u62bd\u51fa\u3068\u51e6\u65b9\u76e3\u67fb\u3078\u306e\u5fdc\u7528\uff0d. \u533b\u7642\u85ac\u5b66 33, 145-151, 2007.<\/p>\n

 <\/p>\n

5. \u65e9\u52e2\u4f38\u6b63, \u7c9f\u5c4b\u654f\u96c4, \u5927\u6edd\u5eb7\u4e00, \u677e\u539f\u548c\u592b, Carter BL. \u9ad8\u8840\u5727\u6cbb\u7642\u85ac\u306e\u65e5\u5e38\u51e6\u65b9\u306b\u304a\u3051\u308b\u85ac\u7269\u9593\u76f8\u4e92\u4f5c\u7528 2\u5264\u4f75\u7528\u306e\u91cd\u8981\u5ea6\u5225\u767a\u751f\u983b\u5ea6\u306b\u95a2\u3059\u308b\u65e5\u7c73\u9593\u6bd4\u8f03. \u533b\u7642\u85ac\u5b66 33, 213-220, 2007.<\/p>\n

 <\/p>\n

6. \u76f8\u6fa4\u4ec1\u5fd7, \u6fa4\u7530\u6f64, \u6cb9\u5ddd\u967d\u5b50, \u9f4b\u85e4\u53f8, \u698e\u672c\u96ea, \u7267\u7530\u572d\u5f18, \u83ca\u6c60\u5065\u6b21\u90ce, \u7530\u5d0e\u5609\u4e00, \u677e\u539f\u548c\u592b. L-DOPA\u306e\u7d4c\u53e3\u6295\u4e0e\u306f\u767d\u8840\u7403\u5185ROS\u3092\u4f4e\u4e0b\u3055\u305b\u308b. \u81e8\u5e8a\u795e\u7d4c\u5b66 47, 1149, 2007.<\/p>\n

 <\/p><\/div>\n

2006\u5e74 \u539f\u8457\u8ad6\u6587<\/h4>\n
\n

1. K. Shimizu, K. Matsubara, K. Ohtaki, O. Saito, T. Awaya, M. Asari, J. Azumi, H. Shiono, S. Yoshiyagawa, Y. Tsunoda. Death by intravenous self-injection of Pacoma, a cationic detergent. Forensic Sci Int<\/i>, 173(1):83-84, 2007.<\/p>\n

 <\/p>\n

2. K. Matsubara, K. Shimizu, M. Suno, K. Ogawa, T. Awaya, T. Yamada, T. Noda, M. Satomi, K. Ohtaki, K. Chiba, Y. Tasaki, H. Shiono. Tnadospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions. Brain Res 1112(1), 126-133, 2006.<\/p>\n

 <\/p>\n

3. K. Aoyama, K. Matsubara, S. Kobayashi. Aging and oxidative stress in progressive supranuclear palsy. Eur J Neurol 13, 89-92, 2006.<\/p>\n

 <\/p><\/div>\n

2005\u5e74 \u539f\u8457\u8ad6\u6587<\/h4>\n
\n

1. M. Kobayashi , H. Saitoh, M. Yamaguchi, T. Saito, H. Fujita, M. Suno, K. Matsubara. B.J. Aungst, Relationship between loperamide-induced sedative effect and digoxin pharmacokinetics in healthy Japanese subjects. Pharm Res 22, 413-418, 2005.<\/p>\n

 <\/p>\n

2. T. Awaya, K. Ohtaki, T. Yamada, K. Yamamoto, T. Miyoshi, Y. Itagaki, Y. Tasaki, N. Hayase and K. Matsubara. Automation in drug inventory management saves personnel time and budget. YAKUGAKUZASSHI 125, 427-432, 2005.<\/p>\n

 <\/p>\n

3. Takayama K, Yuhki K, Ono K, Fujino T, Hara A, Yamada T, Kuriyama S, Karibe H, Okada Y, Takahata O, Taniguchi T, Iijima T, Iwasaki H, Narumiya S, Ushikubi F. Thromboxane A2 and prostaglandin F2alpha mediate inflammatory tachycardia. Nat Med 11, 562-566, 2005.<\/p>\n

 <\/p>\n

4. Y. Kotake, R. Taguchi, K. Okuda, Y. Sekiya, Y. Tasaki, M. Hirobe and S. Ohta. Neuroprotective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline on cultured rat mesencephalic neurons in the presence or absence of various neurotoxins. Brain Res 1033, 143-150, 2005.<\/p>\n

 <\/p>\n

5. \u5409\u7530\u5c06\u4e9c, \u9808\u91ce\u5b66, \u6d45\u5229\u512a, \u5c0f\u5ddd\u7814\u4eba, \u7c9f\u5c4b\u654f\u96c4, \u6e05\u6c34\u6075\u5b50, \u677e\u539f\u548c\u592b, \u5317\u9032\u4e00, \u5869\u91ce\u5bdb. \u9673\u65e7\u5316\u3057\u305f\u6b6f\u7259\u304b\u3089\u306eDNA\u3092\u7528\u3044\u305f\u6027\u5225\u5224\u5b9a. \u5317\u6d77\u9053\u533b\u5b66\u96d1\u8a8c 80, 191-199, 2005.<\/p>\n

 <\/p>\n

6. \u6d45\u5229\u512a, \u5b89\u7a4d\u9806\u4e00, \u5869\u91ce\u5bdb, \u677e\u539f\u548c\u592b. DNA\u591a\u578b\u306e\u81e8\u5e8a\u5fdc\u7528 ABC\u30c8\u30e9\u30f3\u30b9\u30dd\u30fc\u30bf\u30fcABCG2\/BCRP\u306e\u907a\u4f1d\u5b50\u591a\u578b\u89e3\u6790. DNA\u591a\u578b 13, 232-235, 2005.<\/p>\n

 <\/p>\n

7. \u7c9f\u5c4b\u654f\u96c4, \u5927\u6edd\u5eb7\u4e00, \u77f3\u539f\u660c\u53f8, \u5c0f\u91ce\u5c1a\u5fd7, \u5343\u8449\u85ab, \u677f\u57a3\u7950\u4e00, \u5c71\u7530\u6b66\u5b8f, \u9808\u91ce\u5b66, \u65e9\u52e2\u4f38\u6b63, \u7530\u5d0e\u5609\u4e00, \u677e\u539f\u548c\u592b. \u6ce8\u5c04\u85ac\u3092\u542b\u3081\u305f\u76f8\u4e92\u4f5c\u7528\u30c1\u30a7\u30c3\u30af\u30b7\u30b9\u30c6\u30e0\u306b\u3088\u308b\u4f75\u7528\u7981\u5fcc\u306e\u89e3\u6790\uff0d\u85ac\u6b74\u306e\u4e2d\u3067\u306e\u76f8\u4e92\u4f5c\u7528\u30c1\u30a7\u30c3\u30af\u306e\u91cd\u8981\u6027. \u533b\u7642\u85ac\u5b66 31, 425-434, 2005.<\/p>\n

 <\/p>\n

8. \u539f\u5343\u6075\u5b50, \u5c0f\u679d\u6b63\u5409, \u5c71\u4e0b\u606d\u7bc4, \u85e4\u4e38\u30b5\u30e4\u30ab, \u5927\u6edd\u5eb7\u4e00 ,\u68ee\u7530\u771f\u7531\u7f8e, \u5c0f\u91ce\u5c1a\u5fd7, \u5c71\u7530\u6b66\u5b8f, \u677f\u57a3\u5065\u592a\u90ce, \u9808\u91ce\u3042\u3065\u307f, \u5229\u5ca1\u679c\u7f8e, \u77f3\u738b\u5fdc\u77e5, \u6751\u4e0a\u77e5\u5b50, \u6734\u7d18\u6176, \u9808\u91ce\u5b66, \u7c9f\u5c4b\u654f\u96c4, \u5c0f\u5ddd\u8061, \u9ad8\u6a4b\u8ce2\u5c1a, \u5c71\u672c\u4e45\u4ec1\u5b50, \u677f\u57a3\u7950\u4e00, \u5343\u8449\u85ab, \u4e09\u597d\u654f\u4e4b, \u7b20\u539f\u76f4\u90a6, \u85e4\u7530\u80b2\u5fd7, \u7530\u5d0e\u5609\u4e00, \u65e9\u52e2\u4f38\u6b63, \u677e\u539f\u548c\u592b. \u5165\u9662\u65e5\u6301\u53c2\u85ac\u30c1\u30a7\u30c3\u30af\u306f\u533b\u7642\u306e\u5b89\u5168\u6027\u306b\u5bc4\u4e0e\u3059\u308b\uff0d\u6301\u53c2\u85ac\u30c1\u30a7\u30c3\u30af\u7ba1\u7406\u85ac\u5264\u5e2b\u306e\u5f79\u5272\uff0d. \u533b\u7642\u85ac\u5b66 31, 360-366, 2005.<\/p>\n

 <\/p><\/div>\n

2004\u5e74 \u539f\u8457\u8ad6\u6587<\/h4>\n
\n

1. K. Ohtaki, K. Matsubara, S. Fujimaru, K. Shimizu, T. Awaya, M. Suno, K. Chiba, N. Hayase and H. Shiono. Cefoselis a _-lactam antibiotic, easily penetrates the blood-brain barrier and causes seizure independently by glutamate release. J Neural Transm 112, 1523-1535, 2004.<\/p>\n

 <\/p>\n

2. Carter B. L, Lund B. C, Hayase N and Chrischilles E. A longitudinal analysis of antihypertensive drug interactions in a Medicaid population. Am. J. Hypertens 5 Pt 1, 421-427, 2004.<\/p>\n

 <\/p>\n

3. \u677f\u57a3\u5065\u592a\u90ce, \u677f\u57a3\u7950\u4e00, \u5927\u6edd\u5eb7\u4e00, \u5c0f\u91ce\u5c1a\u5fd7, \u68ee\u7530\u771f\u7531\u7f8e, \u85e4\u4e38\u30b5\u30e4\u30ab, \u7c9f\u5c4b\u654f\u96c4, \u4e09\u597d\u654f\u4e4b, \u5c0f\u5ddd\u8061, \u7b20\u539f\u76f4\u90a6, \u85e4\u7530\u80b2\u5fd7, \u7530\u5d0e\u5609\u4e00, \u677e\u539f\u548c\u592b, \u65e9\u52e2\u4f38\u6b63. \u5065\u5eb7\u98df\u54c1\u306b\u5bfe\u3059\u308b\u533b\u5e2b\u306e\u610f\u8b58. \u5317\u6d77\u9053\u75c5\u9662\u85ac\u5264\u5e2b\u4f1a\u8a8c 37, 33-37, 2004.<\/p>\n

 <\/p>\n

4. \u9808\u91ce\u5b66, \u7b20\u539f\u76f4\u90a6, \u5343\u8449\u85ab, \u7c9f\u5c4b\u654f\u96c4, \u5c71\u4e0b\u606d\u7bc4, \u5c0f\u679d\u6b63\u5409, \u9ad8\u6a4b\u8ce2\u5c1a, \u5927\u6edd\u5eb7\u4e00, \u5c71\u672c\u4e45\u4ec1\u5b50, \u85e4\u7530\u80b2\u5fd7, \u65e9\u52e2\u4f38\u6b63, \u52a0\u85e4\u5343\u6d25\u5b50, \u7a32\u8449\u4e45\u5b50, \u4e0a\u7530\u9806\u5b50, \u677e\u539f\u548c\u592b. \u6ce8\u5c04\u85ac\u8a08\u91cf\u8abf\u5264\u306e\u305f\u3081\u306e\u300c\u6df7\u6ce8\u30bb\u30f3\u30bf\u30fc\u300d\u306e\u8a2d\u7f6e\u3068\u305d\u306e\u52b9\u679c\u5b89\u5168\u7ba1\u7406\u3068\u53ce\u76ca\u6027. \u533b\u7642\u85ac\u5b66 30, 88-94, 2004.<\/p>\n

 <\/p>\n

5. \u5c71\u4e0b\u606d\u7bc4, \u5343\u8449\u85ab, \u5c0f\u91ce\u5c1a\u5fd7, \u5c0f\u679d\u6b63\u5409, \u9808\u91ce\u5b66, \u5c0f\u5ddd\u8061, \u7b20\u539f\u76f4\u90a6, \u91cc\u898b\u771f\u77e5\u5b50, \u65e9\u52e2\u4f38\u6b63, \u85e4\u7530\u80b2\u5fd7, \u8c37\u53e3\u6210\u5b9f, \u6cbc\u7530\u7be4, \u6c34\u6c38\u5149\u535a, \u516b\u7af9\u76f4, \u677e\u539f\u548c\u592b. \u5869\u9178\u30aa\u30ad\u30b7\u30d6\u30c1\u30cb\u30f3\u8180\u80f1\u5185\u6ce8\u5165\u7642\u6cd5\u306b\u304a\u3051\u308b\u9577\u671f\u81e8\u5e8a\u4f7f\u7528\u6210\u7e3e\u8abf\u67fb \u96e3\u6cbb\u6027\u5c3f\u5931\u7981\u60a3\u8005\u306eQOL\u3092\u6539\u5584\u3057\u305f\u9662\u5185\u88fd\u5264. \u533b\u7642\u85ac\u5b66 30, 83-87, 2004.<\/p>\n

 <\/p>\n

6. \u5c0f\u91ce\u5c1a\u5fd7, \u5927\u6edd\u5eb7\u4e00, \u7c9f\u5c4b\u654f\u96c4, \u6e21\u8fba\u535a\u6587, \u539f\u5343\u6075\u5b50, \u9ad8\u6a4b\u8ce2\u5c1a, \u5c0f\u5ddd\u8061, \u5c0f\u679d\u6b63\u5409, \u677f\u57a3\u7950\u4e00, \u65e9\u52e2\u4f38\u6b63, \u85e4\u7530\u80b2\u5fd7, \u677e\u539f\u548c\u592b. \u7591\u7fa9\u7167\u4f1a\u652f\u63f4\u30b7\u30b9\u30c6\u30e0\u306e\u69cb\u7bc9\u3068\u904b\u7528 \u30ea\u30b9\u30af\u30de\u30cd\u30b8\u30e1\u30f3\u30c8\u3078\u306e\u6d3b\u7528. \u533b\u7642\u85ac\u5b66 30, 191-197, 2004.<\/p>\n

 <\/p><\/div>\n

2003\u5e74 \u539f\u8457\u8ad6\u6587<\/h4>\n
\n

1. K. Sakurada, K. Matsubara, K. Shimizu, H. Shiono, Y. Seto, K. Tsuge, M. Yoshino, I. Sakai, H. Mukoyama and T. Takatori. Pralidoxime iodide (2-PAM) penetrates across the blood-brain barrier. Neurochem Res 28, 1401-1407, 2003.<\/p>\n

 <\/p>\n

2. K. Shimizu, K. Matsubara, K. Ohtaki, O. Saito and H. Shiono. Paraquat leads to dopaminergic neural vulnerability in organotypic midbrain culture. Neurosci Res 46, 523-532, 2003.<\/p>\n

 <\/p>\n

3. K. Shimizu, K. Matsubara, K. Ohtaki, S. Fujimaru, O. Saito and H. Shiono. Paraquat induces long-lasting dopamine overflow through the excitotoxic pathway in the striatum of freely moving rats. Brain Res 976, 243-252, 2003.<\/p>\n

 <\/p>\n

4. N. Hayase, M. Satomi, A. Hara, T. Awaya, K. Shimizu, and K. Matsubara. Protective effects of quinaprilat and trandolaprilat, active metabolites of quinapril and trandolapril, on hemolysis Induced by lysophosphatidylcholine in human erythrocyte. Biol Pharm Bull 26, 712-716, 2003.<\/p>\n

 <\/p>\n

5. K. Ogawa, M. Suno, K. Shimizu, M. Yoshida, T. Awaya, K. Matsubara and H. Shiono. Genotyping of cytochrome p450 isoform genes is useful for forensic identification of cadaver. Leg Med 5, 132-138, 2003.<\/p>\n

 <\/p>\n

6. K. Matsubara, K. Aoyama, M. Suno, and T. Awaya. N-methylation underlying Parkinson\u2019s disease. Neurotoxicol Teratol 24, 593-598, 2003.<\/p>\n

 <\/p>\n

7. Carter B. L, Chrischilles E, Scholz D, Hayase N. and Nancy B. Extent of services provided by pharmacists performing Iowa pharmaceutical case management. J. Am. Pharm. Assoc 43, 24-33, 2003.<\/p>\n

 <\/p>\n

8. \u9808\u91ce\u5b66, \u7c9f\u5c4b\u654f\u96c4, \u5927\u6edd\u5eb7\u4e00, \u9752\u5c71\u6643\u53f8, \u677e\u539f\u548c\u592b. Nicotinamide N-methyltransferase(NNMT) 5\u2032franking region\u306b\u304a\u3051\u308b\u5909\u7570(-228A\/T)\u691c\u51fa\u6cd5\u306e\u78ba\u7acb\u304a\u3088\u3073\u65e5\u672c\u4eba\u306b\u304a\u3051\u308b\u983b\u5ea6\u89e3\u6790. DNA\u591a\u578b 11, 209-211, 2003.<\/p>\n

 <\/p>\n

9. \u7b39\u5cf6\u552f\u535a, \u8d8a\u6e56\u9032, \u6751\u6728\u5c02\u4e00, \u5343\u8449\u85ab, \u6a58\u5cf0\u53f8. \u6297\u611f\u67d3\u6027\u4eba\u5de5\u8840\u7ba1\u306e\u7814\u7a76:\u7d30\u83cc\u611f\u67d3\u306b\u5bfe\u3059\u308b\u30ea\u30d5\u30a1\u30f3\u30d4\u30b7\u30f3\u7d50\u5408\u30bc\u30e9\u30c1\u30f3\u88ab\u8986\u4eba\u5de5\u8840\u7ba1\u306e\u9069\u7528\u5236\u9650. \u5916\u79d1\u6cbb\u7642 88, 384-385, 2003.<\/p>\n

 <\/p><\/div>\n

2002\u5e74 \u539f\u8457\u8ad6\u6587<\/h4>\n
\n

1. T. Uezono, H. Shiono, K. Shimizu, K. Ogawa, M. Saito, M. Yoshida, H. Mizukami and K. Matsubara. Simultaneous analyses of hypoglycemic agents and C-peptide are essential in a homicide case with the combined dosing insulin and insulin-releasing drug. Leg Med 4, 34-36, 2002.<\/p>\n

 <\/p>\n

2. M. suno, T. Awaya, K. Ogawa, K. Ohtaki, K. Chiba, N. Hayase and K. Matsubara. A wax-mediated hot-start polymerase chain reaction improves the genotyping of CYP2C9*1 and *3 alleles. Jpn J Clin Pharmacol 33, 215-218, 2002.<\/p>\n

 <\/p>\n

3. Koshiko S, Sasajima T, Muraki S, Azuma N, Yamazaki K, Chiba K, Tachibana M, Inaba M. Limitations in the use of rifampicin-gelatin grafts against virulent organisms. J. Vascular Surgery 35, 779-785, 2002.<\/p>\n

 <\/p>\n

4. Carter B. L, Lund B. C, Hayase N, and Chrischilles E. The extent of potential antihypertensive drug interactions in a medicaid population. Am. J. Hypertens 15, 953-957, 2002.<\/p>\n

 <\/p>\n

5. \u68ee\u7530\u771f\u6a39\u5b50, \u5343\u8449\u85ab, \u5c71\u4e0b\u606d\u7bc4, \u7c9f\u5c4b\u654f\u96c4, \u5c0f\u91ce\u5c1a\u5fd7, \u5c0f\u679d\u6b63\u5409, \u9808\u91ce\u5b66, \u7b20\u539f\u76f4\u90a6, \u6e21\u8fba\u535a\u6587, \u85e4\u7530\u80b2\u5fd7, \u65e9\u52e2\u4f38\u6b63, \u677e\u539f\u548c\u592b. \u6ce8\u5c04\u7528\u6297\u83cc\u85ac\u306e\u4f7f\u7528\u52d5\u5411\u3068MRSA\u691c\u51fa\u6570\u3068\u306e\u95a2\u4fc2. \u5317\u6d77\u9053\u75c5\u9662\u85ac\u5264\u5e2b\u4f1a\u8a8c 36, 21-27, 2002.<\/p>\n

 <\/p>\n

6. \u7530\u4e2d\u7406\u4f73, \u5c0f\u5ddd\u8061, \u98ef\u585a\u7950\u5b50, \u5927\u6751\u7f8e\u9999, \u65e9\u52e2\u4f38\u6b63, \u5927\u69fb\u4f38\u5b50, \u677e\u539f\u548c\u592b. 00\u6cbb\u9a13\u540c\u610f\u53d6\u5f97\u306e\u30d7\u30ed\u30bb\u30b9\u306b\u304a\u3051\u308b\u770b\u8b77\u8077\u6cbb\u9a13\u30b3\u30fc\u30c7\u30a3\u30cd\u30fc\u30bf\u30fc\u306e\u6709\u7528\u6027 \u30a2\u30f3\u30b1\u30fc\u30c8\u306b\u3088\u308b\u6cbb\u9a13\u53c2\u52a0\u6c7a\u5b9a\u8981\u56e0\u306e\u5206\u6790. \u770b\u8b77\u6280\u8853 48, 100-104, 2002.<\/p>\n

 <\/p>\n

7. \u5343\u8449\u85ab, \u5bae\u5d0e\u52dd\u5df3, \u677f\u8c37\u5e78\u4e00, \u4f50\u85e4\u8aa0\u4e8c, \u9ad8\u6a4b\u4fdd\u5fd7, \u677e\u539f\u548c\u592b. \u75c5\u68df\u696d\u52d9\u306b\u3088\u308a\u4f7f\u7528\u958b\u59cb\u3055\u308c\u305f\u9662\u5185\u7279\u6b8a\u88fd\u5264\u306b\u95a2\u3059\u308b\u30a2\u30f3\u30b1\u30fc\u30c8. \u533b\u7642\u85ac\u5b66 28, 41-46, 2002.<\/p>\n

 <\/p><\/div>\n

2001\u5e74 \u539f\u8457\u8ad6\u6587<\/h4>\n
\n

1. T. Uezono, W. Maruyama, K. Matsubara, M. Naoi, K. Shimizu, O. Saito, K. Ogawa, izukami,N.Hayase, and H. Shiono. Norharman, indoleamine-derived beta-carboline, but not Trp-P-2, a gamma-carboline, induces apoptotic cell death in human neuroblastoma SH-SY5Y cells. J Neural Transm 108, 943-953, 2001.<\/p>\n

 <\/p>\n

2. K. Aoyama, K. Matsubara, M.o Kondo, Y. Murakawa, M. Suno, K.Yamashita, S. Yamaguchi and S. Kobayashi. Incresed activity of nicotinamide-N-methyltansferase in cerebrospinal fluids of patients with Parkinson\u2019s disease. Neurosci Lett 98, 943-953, 2001.<\/p>\n

 <\/p>\n

3. K. Shimizu, K. Ohtaki, K. Matsubara, K. Aoyama, T. Uezono, O. Saito, M. Suno, N. Hayase, K. Kimura and H. Shiono. Carrier mediated processes in blood-brain barrier penetration and neural uptake of paraquat: a microdialysis study. Brain Res 906, 135-142, 2001.<\/p>\n

 <\/p>\n

4. T. Uezono, K. Matsubara, K. Shimizu, H. Mizukami, K. Ogawa, O. Saitoa, N. Hayase, H. Eto, K. Kimura and H. Shiono. Glutamate is not involved in the MPP+ -induced dopamine overflow in the striatum of freely moving C57BL\/6 mice. J Neural Transm 108, 899-908, 2001.<\/p>\n

 <\/p>\n

5. K. Matsubara, T. Senda, T. Uezono, T. Awaya, S. Ogawa, K. Chiba, K. Shimizu, N. Hayase and K. Kimura. L-Deprenyl prevents the cell hypoxia induced by dopaminergic neurotoxins, MPP+ and beta-carbolinium: A microdialysis study in rats. Neurosci Lett 302, 65-68, 2001.<\/p>\n

 <\/p>\n

6. \u5c0f\u5ddd\u8061, \u7530\u4e2d\u91cc\u4f73, \u5927\u6751\u7f8e\u9999, \u4e09\u597d\u654f\u4e4b, \u7af9\u672c\u529f, \u65e9\u52e2\u4f38\u6b63, \u677e\u539f\u548c\u592b. \u30b3\u30fc\u30c7\u30a3\u30cd\u30fc\u30bf\u30fc\u306e\u4ecb\u5165\u306b\u3088\u308a\u5b9f\u65bd\u7387\u306e\u5411\u4e0a\u3057\u305f\u6cbb\u9a13\u306e\u5206\u6790 \u88ab\u9a13\u8005\u53ca\u3073\u6cbb\u9a13\u62c5\u5f53\u533b\u5e2b\u3078\u306e\u30a2\u30f3\u30b1\u30fc\u30c8\u304b\u3089. \u65e5\u75c5\u85ac\u8a8c 37, 1607-1616, 2001.<\/p>\n

 <\/p>\n

7. \u65e9\u52e2\u4f38\u6b63, \u6751\u7530\u3042\u3065\u307f, \u5ca1\u672c\u7f8e\u6a39, \u5409\u7530\u4fee\u5b50, \u5927\u6edd\u5eb7\u4e00, \u9ad8\u6a4b\u8ce2\u5c1a, \u5c0f\u5ddd\u8061, \u539f\u5343\u6075\u5b50, \u677f\u57a3\u7950\u4e00, \u5c71\u672c\u4e45\u4ec1\u5b50, \u4e09\u597d\u654f\u4e4b, \u963f\u4e45\u6d25\u8302\u9686, \u4f50\u85e4\u91cd\u653f, \u7531\u4e95\u5247\u4e4b, \u677e\u539f\u548c\u592b. \u5916\u6765\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305f\u300c\u85ac\u306e\u98f2\u307f\u65b9\u300d\u306b\u95a2\u3059\u308b\u5b9f\u614b\u8abf\u67fb \u670d\u85ac\u6307\u5c0e\u3078\u306e\u6d3b\u7528. \u65e5\u75c5\u85ac\u8a8c 37, 33-35, 2001.<\/p>\n

 <\/p>\n

8. A. Storch, S. Ohta, Y-I. Hwang, R. Ortmann, A. Hein, S. Frenzel, K. Matsubara, M. A. Collins, S. Ohta. Selective dopaminergic neurotoxicity of isoquinoline derivatives related to Parkinson!s disease: Studies using heterologous expression systems of the dopamine transporter H-U. Wolff, J. Schwarzg Biochem Pharmacol 163, 909-920, 2001.<\/p>\n

 <\/p><\/div>\n

2000\u5e74 \u539f\u8457\u8ad6\u6587<\/h4>\n
\n

1. K. Aoyama, K. Matsubara, K. Okada, S. Fukushima, K. Shimizu, S. Yamaguchi, T. Uezono, M. Satomi, N. Hayase, S. Ohta, H. Shiono and S. Kobayashi. N-Methylation ability for azaheterocyclic amines is higher in Parkinson\u2019s disease: nicotinamide loading test. J Neural Transm 107, 985-995, 2000.<\/p>\n

 <\/p>\n

2. K. Aoyama, K. Matsubara, Y. Hujikawa, Y. Nagahiro, K. Shimizu, N. Umegae, N. Hayase, H. Shiono, and S.Kobayashi. Nitration of manganese superoxide dismutase in cerebrospinal fluids is a marker for peroxynitrite mediated oxidative stress in neurodegenerative diseases. Ann Neurol 47, 524-527, 2000.<\/p>\n

 <\/p>\n

3. K. Shimizu, H. Shiono, K. Matsubara, T. Awaya, T. Takahashi, O. Saito, H. Mizukami, T. Uezono and H. K. Akutsu. Tissue distribution of lidocaine in acute death due to overdosing. Legal Med 2101-105, 2000.<\/p>\n

 <\/p>\n

4. K. Sango, W. Maruyama, K. Matsubara, P. Dostert, C. Minami, M, Kawai and M. Naoi. Enantio-selective occurence of (S)-tetrahydropapaveroline in human brain. Neurosci Lett 283, 224-226, 2000.<\/p>\n

 <\/p>\n

5. \u65e9\u52e2\u4f38\u6b63, \u5c0f\u679d\u6b63\u5409, \u7c9f\u5c4b\u654f\u96c4, \u539f\u5343\u6075\u5b50, \u5c71\u4e0b\u606d\u7bc4, \u5c71\u672c\u4e45\u4ec1\u5b50, \u677f\u57a3\u7950\u4e00, \u677e\u539f\u548c\u592b. \u7d4c\u76ae\u5438\u53ce\u578b\u785d\u9178\u30c6\u30fc\u30d7\u5264\u306e\u526f\u4f5c\u7528\u3068\u3057\u3066\u306e\u76ae\u819a\u523a\u6fc0\u6027\u306b\u6709\u52b9\u6027\u3068\u7d4c\u6e08\u6027\u3092\u8003\u616e\u3057\u305f\u88fd\u5264\u7684\u8a55\u4fa1\uff0d\u6c34\u5206\u900f\u904e\u6027\u3068\u89d2\u8cea\u7d30\u80de\u5265\u96e2\u91cf\u306e\u6e2c\u5b9a\uff0d. \u75c5\u9662\u85ac\u5b66 26, 510-517, 2000.<\/p>\n

 <\/p>\n

6. \u677f\u57a3\u7950\u4e00, \u85e4\u7530\u80b2\u5fd7, \u5c0f\u679d\u6b63\u5409, \u5c71\u4e0b\u606d\u7bc4, \u5927\u6edd\u5eb7\u4e00, \u5c71\u672c\u4e45\u4ec1\u5b50, \u4e09\u597d\u654f\u4e4b, \u65e9\u52e2\u4f38\u6b63, \u963f\u4e45\u6d25\u8302\u9686, \u7af9\u672c\u529f, \u677e\u539f\u548c\u592b. \u670d\u85ac\u610f\u6b32\u306e\u306a\u3044\u8996\u899a\u969c\u5bb3\u8005\u306b\u5bfe\u3059\u308b\u670d\u85ac\u6307\u5c0e\uff0d\u300c\u8996\u899a\u969c\u5bb3\u8005\u7528\u30b7\u30fc\u30eb\u300d\u3092\u7528\u3044\u3066\u306e\u8a66\u307f\uff0d. \u533b\u85ac\u30b8\u30e3\u30fc\u30ca\u30eb 36, 754-757, 2000.<\/p>\n

 <\/p>\n

7. \u5343\u8449\u85ab, \u539f\u5343\u6075\u5b50, \u9ad8\u6a4b\u8ce2\u5c1a, \u677e\u539f\u548c\u592b, \u702c\u5ddd\u6f84\u5b50, \u524d\u672c\u7be4\u7537, \u9ad8\u5f8c\u88d5. \u30c1\u30fc\u30e0\u533b\u7642\u306b\u304a\u3051\u308b\u85ac\u5264\u696d\u52d9\uff0d\u5927\u8178\u30dd\u30ea\u30da\u30af\u30c8\u30df\u30fc\u306e\u30af\u30ea\u30c6\u30a3\u30ab\u30eb\u30d1\u30b9\u4f5c\u6210\u30fb\u5c0e\u5165\u3078\u306e\u53c2\u753b\uff0d. medical forum CHUGAI 4, 18-25, 2000.<\/p>\n

 <\/p><\/div>\n

1999\u5e74 \u539f\u8457\u8ad6\u6587<\/h4>\n
\n

1. M. Hasegawa, K. Matsubara, S. Fukushima1, C. Maseda, T. Uezono and K. Kimura. Stereoselective analyses and pharamcokinetics of selegiline metabolites: possible urinary markers for selegiline therapy. Forensic Sci Int 101, 95-106, 1999.<\/p>\n

  <\/p><\/div>\n

1998\u5e74 \u539f\u8457\u8ad6\u6587<\/h4>\n
\n

1. K. Matsubara, T. Senda, T. Uezono, S. Fukushima, S. Ohta, K. Igarashi, M. Naoi, Y. Yamashita, K. Ohtaki, N. Hayase, S. Akutsu and K. Kimura. Structural significance of azaheterocyclic amines related to Parkinson\u2019s disease for dopamine transporter. Eur J Pharmacol 348, 77-84, 1998.
\n 
\n2. K. Matsubara, T. Gonda, H. Sawada, T. Uezono, Y. Kobayashi, T. Kawamura, K. Ohtaki, K. Kimura, A. Akaike. Endogenously occurring beta-Carboline induces parkinsonism in non-Primate animals: a possible causative pro-toxin in idiopathic Parkinson\u2019s disease. J Neurochem 70, 727-735, 1998.<\/p>\n

 <\/p>\n

3. K. Shimizu, K. Matsubara, T. Uezono, K. Kimura and H. Shiono. Reduced dorsal hippocampal glutamate release significantly correlates with the spatial memory deficits produced by benzodiazepines and ethanol. Neuroscience 83, 701-706, 1998.<\/p>\n

 <\/p>\n

4. \u7af9\u672c\u529f, \u7c9f\u5c4b\u654f\u96c4, \u5c71\u672c\u4e45\u4ec1\u5b50, \u539f\u5343\u6075\u5b50, \u4e09\u597d\u654f\u4e4b, \u6e21\u8fba\u535a\u6587, \u65e9\u52e2\u4f38\u6b63, \u963f\u4e45\u6d25\u8302\u9686, \u677e\u539f\u548c\u592b. \u4e0d\u826f\u533b\u85ac\u54c1\u306e\u56de\u53ce\u3068\u305d\u306e\u624b\u9806. \u533b\u85ac\u30b8\u30e3\u30fc\u30ca\u30eb 34, 2880-2884, 1998.<\/p>\n

 <\/p>\n

5. \u5c71\u4e0b\u606d\u7bc4, \u5927\u6edd\u5eb7\u4e00, \u5c0f\u679d\u6b63\u5409, \u7c9f\u5c4b\u654f\u96c4, \u9ad8\u6a4b\u8ce2\u5c1a, \u5409\u7530\u4fee\u5b50, \u5ca1\u672c\u7f8e\u6a39, \u85e4\u7530\u80b2\u5fd7, \u5343\u8449\u85ab, \u65e9\u52e2\u4f38\u6b63, \u963f\u4e45\u6d25\u8302\u9686, \u677e\u539f\u548c\u592b. \u65ed\u5ddd\u533b\u79d1\u5927\u5b66\u9644\u5c5e\u75c5\u9662\u306b\u304a\u3051\u308b\u591a\u5264\u6295\u4e0e\u306e\u73fe\u72b6. \u5317\u6d77\u9053\u75c5\u9662\u85ac\u5264\u5e2b\u4f1a\u8a8c 55, 47-54, 1998.<\/p>\n

 <\/p>\n

6. \u9577\u8c37\u5ddd\u6b63\u7d00, \u9593\u702c\u7530\u5343\u9999\u6681, \u798f\u5cf6\u6b63\u5145, \u4e0a\u5712\u5d07, \u677f\u57a3\u7950\u4e00, \u65e9\u52e2\u4f38\u6b63, \u6728\u6751\u6052\u4e8c\u90ce, \u677e\u539f\u548c\u592b. \u30bb\u30ec\u30ae\u30ea\u30f3\u670d\u7528\u8005\u3068\u899a\u305b\u3044\u5264\u6feb\u7528\u8005\u306e\u8b58\u5225\uff0dTriage\u306b\u3088\u308b\u30b9\u30af\u30ea\u30fc\u30cb\u30f3\u30b0\u8a66\u9a13\u306e\u6709\u7528\u6027. \u6cd5\u4e2d\u6bd2\u96d1\u8a8c 16, 200-206, 1998.<\/p>\n

 \n <\/p><\/div>\n<\/div>\n

\u8457\u66f8\u30fb\u7dcf\u8aac(1998\u5e74~2012\u5e74)\u3000\u25bc<\/span><\/h3>\n
\n

2012\u5e74 \u8457\u66f8\u30fb\u7dcf\u8aac<\/h4>\n
\n

1. \u7c9f\u5c4b\u654f\u96c4(\u7de8\u96c6), \u5927\u6edd\u5eb7\u4e00. \u65e5\u672c\u75c5\u9662\u85ac\u5264\u5e2b\u4f1a\u76e3\u4fee \u30d9\u30c3\u30c9\u30b5\u30a4\u30c9\u306e\u81e8\u5e8a\u85ac\u5b66\u3000\u5468\u8853\u671f\u306e\u85ac\u5b66\u7ba1\u7406. 4-7(1-1), 8-9(1-2), 10-11(1-3), 16-18(1-5), 19(1-6), 20-21(1-7), 112-114(2-7), 216-217(5-15), 218-219(5-16), 228(6-4), 229(6-5), 241(6-13), \u5357\u5c71\u5802, \u6771\u4eac, 2012.<\/p>\n

 <\/p>\n

2. \u5927\u6751\u53cb\u535a, \u6d45\u5229\u512a, \u5c71\u672c\u8b72, \u795e\u5c71\u76f4\u4e5f, \u5ca1\u4e45\u7f8e\u5b50, \u4fdd\u79d1\u5343\u91cc, \u9593\u702c\u7530\u5343\u9999\u6681, \u7c9f\u5c4b\u654f\u96c4, \u7530\u5d0e\u5609\u4e00, \u5869\u91ce\u5bdb, \u6e05\u6c34\u60e0\u5b50, \u677e\u539f\u548c\u592b. \u30be\u30cb\u30b5\u30df\u30c9\u306b\u3088\u308bHRD1\u306e\u5897\u52a0\u304c,\u795e\u7d4c\u7d30\u80deSH-SY5Y\u306b\u304a\u3051\u308b\u5c0f\u80de\u4f53\u30b9\u30c8\u30ec\u30b9\u8a98\u767a\u7d30\u80de\u6b7b\u3068\u30ab\u30b9\u30d1\u30fc\u30bc-3\u306e\u6d3b\u6027\u5316\u3092\u6291\u5236\u3059\u308b. \u5317\u6d77\u9053\u533b\u5b66\u96d1\u8a8c 87(6), 251, 2012.<\/p>\n

 <\/p>\n

3. \u6d45\u5229\u512a, \u5927\u6751\u53cb\u535a, \u9593\u702c\u7530\u5343\u9999\u6681, \u5869\u91ce\u5bdb, \u7530\ufa11\u5609\u4e00, \u677e\u539f\u548c\u592b, \u6e05\u6c34\u60e0\u5b50. \u30d7\u30ed\u30fc\u30d63\u2018\u672b\u7aef\u5869\u57fa\u914d\u5217\u306e\u9055\u3044\u306b\u57fa\u3065\u3044\u305f\u4e00\u5869\u57fa\u591a\u578b\u306e\u8b58\u5225. \u5317\u6d77\u9053\u533b\u5b66\u96d1\u8a8c 87(2-3), 67, 2012.<\/p>\n

 <\/p><\/div>\n

2011\u5e74 \u8457\u66f8\u30fb\u7dcf\u8aac<\/h4>\n
\n

1. \u5927\u6751\u53cb\u535a\u30fb\u677e\u539f\u548c\u592b\/\u9752\u5c71\u6643\u6cbb\uff08\u57f7\u7b46\u5354\u529b\uff09. A\u3000\u7cbe\u795e\u8133\u795e\u7d4c\u7cfb\u75be\u60a3\u30003\u7ae0\u3000\u30d1\u30fc\u30ad\u30f3\u30bd\u30f3\u75c5, \u65e5\u672c\u533b\u7642\u85ac\u5b66\u4f1a,\u75c5\u614b\u3092\u7406\u89e3\u3057\u3066\u7d44\u307f\u7acb\u3066\u308b\u3000\u85ac\u5264\u5e2b\u306e\u305f\u3081\u306e\u75be\u60a3\u5225\u85ac\u7269\u7642\u6cd5\u2161\u3000\u7cbe\u795e\u30fb\u8133\u795e\u7d4c\u7cfb\u75be\u60a3\/\u6d88\u5316\u5668\u75be\u60a3, \u5357\u6c5f\u5802, \u6771\u4eac, 36-52, 2011.<\/p>\n

 <\/p>\n

2. \u677e\u539f\u548c\u592b. \u3010\u300c\u53c2\u52a0\u578b\u300d\u5b9f\u52d9\u5b9f\u7fd2\u306f\u3069\u3046\u5b9f\u8df5\u3055\u308c\u305f\u304b\u3011 \u75c5\u9662\u5b9f\u7fd2\u306e\u5b9f\u969b\u3068\u4eca\u5f8c\u306b\u5411\u3051\u3066\u3000\u65ed\u5ddd\u533b\u79d1\u5927\u5b66\u75c5\u9662\u306b\u304a\u3051\u308b\u5b9f\u52d9\u5b9f\u7fd2\u3000\u60a3\u8005\u3092\u4e2d\u5fc3\u3068\u3057\u3066SBOs\u3092\u9054\u6210. \u85ac\u4e8b 53(1), 27-32, 2011.<\/p>\n

 <\/p>\n

3. \u677e\u539f\u548c\u592b. \u7279\u96c6\u3000\u516d\u5e74\u5236\u85ac\u5b66\u6559\u80b2\u306b\u304a\u3051\u308b1\u5e74\u76ee\u306e\u9577\u671f\u5b9f\u52d9\u5b9f\u7fd2\u3092\u7d42\u3048\u3066\u3000\u2462\u75c5\u9662\u306e\u7acb\u5834\u304b\u3089. \u65e5\u672c\u75c5\u9662\u85ac\u5264\u5e2b\u4f1a\u96d1\u8a8c 47(5), 528-530, 2011.<\/p>\n

 <\/p>\n

4. \u677e\u539f\u548c\u592b. \u3010\u5b9f\u52d9\u5b9f\u7fd2\u3092\u3088\u308a\u826f\u304f\u3059\u308b\u305f\u3081\u306b\u3011 \u65e5\u672c\u75c5\u9662\u85ac\u5264\u5e2b\u4f1a\u306e\u7acb\u5834\u304b\u3089. \u533b\u85ac\u30b8\u30e3\u30fc\u30ca\u30eb 47(5), 1422-1431, 2011.<\/p>\n

 <\/p>\n

5. \u4e95\u4e0a\u6b63\u671d. Close up\u3000\u75c5\u9662\u72ec\u81ea\u306e\u30d7\u30ed\u30b0\u30e9\u30e0\u3067\u3058\u3063\u304f\u308a\u6307\u5c0e\u3000\u85ac\u5264\u5e2b\u5598\u606f\u5916\u6765. GSK pharmacist journal 33(7), 8-10, 2011. <\/p>\n

 <\/p><\/div>\n

2009\u5e74 \u8457\u66f8\u30fb\u7dcf\u8aac<\/h4>\n
\n

1. \u4e09\u597d\u654f\u4e4b. \u533b\u7642\u5b89\u5168\u306b\u5bfe\u3059\u308b\u85ac\u5264\u5e2b\u306e\u5f79\u5272\uff08\u5dfb\u982d\u8a00\uff09. \u5317\u6d77\u9053\u75c5\u9662\u85ac\u5264\u5e2b\u4f1a\u8a8c 76:5, 2009.<\/p>\n

 <\/p><\/div>\n

2008\u5e74 \u8457\u66f8\u30fb\u7dcf\u8aac<\/h4>\n
\n

1. \u677e\u539f\u548c\u592b, \u6885\u6d25\u5178\u5b50. \u60a3\u8005\u306e\u75c5\u614b\u30fb\u75c5\u72b6\u628a\u63e1\u306e\u305f\u3081\u306b\u306f\u4f55\u304c\u5fc5\u8981\u304b\u3000\u8a3a\u7642\u8a18\u9332\u3068\u305d\u306e\u5229\u7528\u6cd5\uff08\u7279\u96c6\u3000\u75c5\u68df\u696d\u52d9\u3078\u306e\u30a2\u30d7\u30ed\u30fc\u30c1\uff0d\u6c42\u3081\u3089\u308c\u308b\u8cc7\u8cea\u3068\u30b9\u30ad\u30eb\uff09. \u85ac\u4e8b 50, 567-571, 2008.<\/p>\n

 <\/p>\n

2. \u5c71\u7530\u6b66\u5b8f, \u7db1\u5ddd\u667a\u4e4b. \u60a3\u8005\u306e\u3053\u3068\u3070. \u8abf\u5264\u3068\u60c5\u5831, 2008.<\/p>\n

 <\/p>\n

3. \u5c0f\u91ce\u5c1a\u5fd7, \u677e\u539f\u548c\u592b. \u5438\u5165\u7642\u6cd5\uff0d\u6c17\u7ba1\u652f\u5598\u606f\u30fbCOPD\uff0d\u5438\u5165\u65b9\u6cd5\u3067\u77e5\u308a\u305f\u3044\u3053\u3068. \u85ac\u5c40 59, 2377-2380, 2008.<\/p>\n

 <\/p>\n

4. \u677e\u539f\u548c\u592b, \u6885\u6d25\u5178\u5b50. \u75c5\u68df\u696d\u52d9\u3078\u306e\u30a2\u30d7\u30ed\u30fc\u30c1-\u6c42\u3081\u3089\u308c\u308b\u8cc7\u8cea\u3068\u30b9\u30ad\u30eb. \u85ac\u4e8b 50, 567-571, 2008.<\/p>\n

 <\/p>\n

5. \u5927\u6edd\u5eb7\u4e00, \u6885\u6d25\u5178\u5b50, \u9ebb\u4e0b\u667a\u52a0, \u4e03\u7530\u77e5\u7f8e, \u90fd\u7bc9\u4ec1\u7f8e, \u77f3\u5ddd\u7965\u5b50, \u5b89\u9054\u77e5\u8f1d, \u4e95\u4e0a\u6b63\u671d, \u5c0f\u91ce\u5c1a\u5fd7, \u5c71\u7530\u6b66\u5b8f, \u7c9f\u5c4b\u654f\u96c4, \u5c0f\u5ddd\u8061, \u91cc\u898b\u771f\u77e5\u5b50, \u91ce\u7530\u654f\u5b8f, \u7530\ufa11\u5609\u4e00, \u677f\u57a3\u7950\u4e00, \u516b\u6728\u771f\u7802\u5b50, \u7530\u5c3e\u597d\u6b63, \u7b20\u539f\u76f4\u90a6, \u85e4\u6fa4\u82b3\u5247, \u677e\u91ce\u548c\u5f66, \u677e\u539f\u548c\u592b. \u85ac\u85ac\u9023\u643a\uff0d\u75c5\u9662\u85ac\u5264\u5e2b\u304c\u4ecb\u5728\u3059\u308b\u4fdd\u967a\u8abf\u5264\u85ac\u5c40\u304b\u3089\u306e\u30c8\u30ec\u30fc\u30b7\u30f3\u30b0\u30ec\u30dd\u30fc\u30c8\u30b7\u30b9\u30c6\u30e0\u306b\u3088\u308b\u85ac\u7269\u7642\u6cd5\u306e\u6709\u52b9\u6027\u30fb\u5b89\u5168\u6027\u3078\u306e\u5bc4\u4e0e. \u533b\u85ac\u30b8\u30e3\u30fc\u30ca\u30eb 44, 158-164, 2008.<\/p>\n

 <\/p><\/div>\n

2006\u5e74 \u8457\u66f8\u30fb\u7dcf\u8aac<\/h4>\n
\n

1. \u5343\u8449\u85ab, \u677e\u539f\u548c\u592b. \u305d\u306e\u4ed6\u306e\u6d88\u5316\u7ba1\u75be\u60a3\u6cbb\u7642\u85ac(\u6f70\u760d\u6027\u5927\u8178\u708e\u3001\u81b5\u708e\u6cbb\u7642\u85ac\u3001\u80c6\u77f3\u6eb6\u89e3\u85ac\u306a\u3069) In: \u75c5\u6c17\u3068\u85ac\u306e\u8aac\u660e\u30ac\u30a4\u30c92006, pp1127-1144, \u5357\u5c71\u5802\uff0c\u6771\u4eac, 2006.<\/p>\n

 <\/p>\n

2. \u677e\u539f\u548c\u592b, \u5c0f\u679d\u6b63\u5409, \u539f\u5343\u6075\u5b50, \u5343\u8449\u85ab, \u7530\u5d0e\u5609\u4e00. \u5165\u9662\u6642\u6301\u53c2\u85ac\u306e\u5b89\u5168\u7ba1\u7406\u306b\u5411\u3051\u3066\u3000\u65ed\u5ddd\u533b\u79d1\u5927\u5b66\u75c5\u9662\u306e\u53d6\u308a\u7d44\u307f\uff0d\u30d9\u30c3\u30c9\u30b5\u30a4\u30c9\u3067\u884c\u3046\u6301\u53c2\u85ac\u30c1\u30a7\u30c3\u30af\u306f\u533b\u7642\u306e\u5b89\u5168\u306b\u5bc4\u4e0e\u3059\u308b. \u85ac\u4e8b 48, 833-839, 2006.<\/p>\n

 <\/p>\n

3. \u677e\u539f\u548c\u592b, \u5927\u6edd\u5eb7\u4e00. \u6cbb\u7642\u306b\u304a\u3051\u308b\u6700\u8fd1\u306e\u65b0\u85ac\u306e\u4f4d\u7f6e\u4ed8\u3051\uff0d\u65b0\u85ac\u306e\u5e83\u5834\uff0d\u6ce8\u5c04\u7528\u6297\u83cc\u85ac. \u533b\u85ac\u30b8\u30e3\u30fc\u30ca\u30eb 42, 347-353, 2006.<\/p>\n

 <\/p>\n

4.\u3000\u677e\u539f\u548c\u592b. \u7761\u7720\u85ac\u306eomega1\u53d7\u5bb9\u4f53\u306b\u5bfe\u3059\u308b\u4f5c\u7528. \u533b\u4e8b\u65b0\u5831 d4265, 98-99, 2006.<\/p>\n

 <\/p>\n

5. \u5927\u6edd\u5eb7\u4e00. \u60a3\u8005\u306e\u3053\u3068\u30702\u3000\u304b\u304b\u308a\u3064\u3051\u85ac\u5c40\u3092\u5927\u5207\u306b. \u8abf\u5264\u3068\u60c5\u5831 12, 1129-1132, 2006.<\/p>\n

 <\/p><\/div>\n

2005\u5e74 \u8457\u66f8\u30fb\u7dcf\u8aac<\/h4>\n
\n

1. \u677e\u539f\u548c\u592b, \u677f\u57a3\u7950\u4e00, \u5c0f\u679d\u6b63\u5409, \u7b20\u539f\u76f4\u90a6, \u7530\u5d0e\u5609\u4e00. \u60a3\u8005\u306eQOL\u5411\u4e0a\u3068\u85ac\u5264\u5e2b\u306e\u95a2\u308f\u308a\u3000\u533b\u85ac\u5206\u696d\u306e\u5b9f\u8df5\uff0d\u30b5\u30c6\u30e9\u30a4\u30c8\u30d5\u30a1\u30fc\u30de\u30b7\u30fc\u306b\u304a\u3051\u308b\u696d\u52d9\uff0d. \u533b\u85ac\u30b8\u30e3\u30fc\u30ca\u30eb 41, 1241-1248, 2005.<\/p>\n

 <\/p>\n

2. \u677e\u539f\u548c\u592b,\u5c0f\u91ce\u5c1a\u5fd7,\u85e4\u4e38\u30b5\u30e4\u30ab,\u68ee\u7530\u771f\u7531\u7f8e. COPD \u533b\u7642\u30b9\u30bf\u30c3\u30d5\u304b\u3089\u306e\u63d0\u8a00 \u85ac\u5264\u5e2b\u306b\u6c42\u3081\u3089\u308c\u308b\u6c17\u7ba1\u652f\u62e1\u5f35\u85ac\u306e\u5438\u5165\u6307\u5c0e. COPD FRONTIER 4, 340-346, 2005.<\/p>\n

 <\/p>\n

3. \u5c0f\u91ce\u5c1a\u5fd7, \u677e\u539f\u548c\u592b. \u8840\u6813\u585e\u6813\u75c7\u306e\u30cf\u30a4\u30ea\u30b9\u30af\u60a3\u8005\u3078\u306e\u6297\u51dd\u56fa\u7642\u6cd5\u6307\u5c0e In: \u75be\u60a3\u5225\u85ac\u5264\u7ba1\u7406\u6307\u5c0e\u30cf\u30f3\u30c9\u30d6\u30c3\u30af2\uff08\u65e5\u672c\u75c5\u9662\u85ac\u5264\u5e2b\u4f1a\u7de8\uff09, \u30a8\u30eb\u30bc\u30d3\u30a2\u30b8\u30e3\u30d1\u30f3, \u6771\u4eac, pp152-155, 2005.<\/p>\n

 <\/p><\/div>\n

2004\u5e74 \u8457\u66f8\u30fb\u7dcf\u8aac<\/h4>\n
\n

1.\u65e9\u52e2\u4f38\u6b63, \u677e\u539f\u548c\u592b. \u7c73\u56fd\u306e\u85ac\u5264\u5e2b\u6559\u80b2\u30686\u5e74\u5236\u6559\u80b2\u3092\u8003\u3048\u308b\u3000\u7c73\u56fd\u306b\u304a\u3051\u308b\u85ac\u5264\u5e2b\u6559\u80b2. \u533b\u85ac\u30b8\u30e3\u30fc\u30ca\u30eb 40, 1691-1696, 2004.<\/p>\n

 <\/p>\n

2. \u677e\u539f\u548c\u592b, \u7530\u5d0e\u5609\u4e00. \u6cbb\u9a13\u306e\u73fe\u72b6\u3068\u4eca\u5f8c\u306e\u65b9\u5411. \u65ed\u5ddd\u533b\u79d1\u5927\u5b66\u7814\u7a76\u30d5\u30a9\u30fc\u30e9\u30e0 5, 44-48, 2004.<\/p>\n

 <\/p>\n

3. \u7b20\u539f\u76f4\u90a6, \u9808\u91ce\u5b66, \u5c71\u4e0b\u606d\u7bc4, \u539f\u5343\u6075\u5b50, \u5927\u6edd\u5eb7\u4e00, \u7c9f\u5c4b\u654f\u96c4, \u5343\u8449\u85ab, \u677e\u539f\u548c\u592b. \u30ea\u30b9\u30af\u30de\u30cd\u30b8\u30e1\u30f3\u30c8\u3092\u8996\u91ce\u306b\u5165\u308c\u305f\u300c\u6df7\u6ce8\u30bb\u30f3\u30bf\u30fc\u300d\u306e\u958b\u8a2d. \u533b\u85ac\u30b8\u30e3\u30fc\u30ca\u30eb 40, 142-149, 2004.<\/p>\n

 <\/p>\n

4. \u677e\u539f\u548c\u592b, \u9ad8\u6a4b\u8ce2\u5c1a. \u6f70\u760d\u6027\u5927\u8178\u708e In: \u75be\u60a3\u5225\u85ac\u5264\u7ba1\u7406\u6307\u5c0e\u30cf\u30f3\u30c9\u30d6\u30c3\u30af\uff08\u65e5\u672c\u75c5\u9662\u85ac\u5264\u5e2b\u4f1a\u7de8\uff09 pp100-101, \u30a8\u30eb\u30bc\u30d3\u30a2\u30b8\u30e3\u30d1\u30f3, \u6771\u4eac, 2004.<\/p>\n

 <\/p>\n

5. \u677e\u539f\u548c\u592b. \u85ac\u7269\u6fc3\u5ea6 In: \u691c\u67fb\u5024\u3092\u8aad\u3080\uff08\u5185\u79d1\u5897\u5927\u53f7\uff09 pp1473-1475, \u5357\u6c5f\u5802, \u6771\u4eac, 2004.<\/p>\n

 <\/p>\n

6. \u65e9\u52e2\u4f38\u6b63, \u677e\u539f\u548c\u592b. \u80ba\u7d50\u6838 In: \u30d7\u30ed\u30b0\u30e9\u30e0\u5b66\u7fd2\u306b\u3088\u308b\u51e6\u65b9\u89e3\u6790\u5b66\uff08\u4e95\u95a2\u5065, \u5ca9\u5ddd\u7cbe\u543e, \u5ca1\u91ce\u5584\u90ce, \u7247\u5ca1\u6cf0\u6587, \u4e0a\u80fd\u4f0a\u516c\u96c4, \u677e\u5c71\u8ce2\u6cbb, \u5c71\u7530\u5b89\u5f66\u7de8\uff09 pp 174-179, \u5ee3\u5ddd\u66f8\u5e97, \u6771\u4eac, 2004.<\/p>\n

 <\/p><\/div>\n

2003\u5e74 \u8457\u66f8\u30fb\u7dcf\u8aac<\/h4>\n
\n

1. \u677e\u539f\u548c\u592b, \u5927\u6edd\u5eb7\u4e00. \u6700\u8fd1\u306e\u65b0\u85ac\u3092\u6cbb\u7642\u306b\u3069\u3046\u6d3b\u304b\u3059\u304b\u3000\u50ac\u7720\u30fb\u93ae\u9759\u85ac. \u533b\u85ac\u30b8\u30e3\u30fc\u30ca\u30eb 37, 33-35, 2003.<\/p>\n

 <\/p>\n

2. \u677e\u539f\u548c\u592b. \u3053\u3046\u3057\u3066\u9023\u643a\u3057\u3066\u307e\u3059\uff01\uff0d\u85ac\u5264\u5e2b\u306e\u6d3b\u8e8d\u3059\u308b\u75c5\u9662.\u30ca\u30fc\u30b7\u30f3\u30b0\u30fb\u30c8\u30a5\u30c7\u30a4 18, 131-133, 2003.<\/p>\n

 <\/p>\n

3. \u677e\u539f\u548c\u592b. \u30d1\u30fc\u30ad\u30f3\u30bd\u30f3\u75c5\u306e\u767a\u75c7\u306b\u95a2\u4e0e\u3059\u308b\u56e0\u5b50. \u65ed\u5ddd\u533b\u79d1\u5927\u5b66\u7814\u7a76\u30d5\u30a9\u30fc\u30e9\u30e0 14, 4-14 , 2003.<\/p>\n

 <\/p>\n

4. \u9808\u91ce\u3000\u5b66, \u65e9\u52e2\u4f38\u6b63, \u677e\u539f\u548c\u592b. \u6700\u65b0\u306e\u6cbb\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u3000\u9ad8\u8102\u8840\u75c7\u30fb\u52d5\u8108\u786c\u5316\u75c7 \u5317\u6d77\u9053\u85ac\u5264\u5e2b\u4f1a\u96d1\u8a8c 20, 2-6, 2003.<\/p>\n

 <\/p>\n

5. \u677e\u539f\u548c\u592b. \u9662\u5185\u3067\u5e83\u304c\u308b\u85ac\u5264\u5e2b\u8077\u80fd\u3000\u85ac\u5264\u696d\u52d9\u306e\u65b0\u305f\u306a\u8ab2\u984c: \u30b5\u30c6\u30e9\u30a4\u30c8\u30d5\u30a1\u30fc\u30de\u30b7\u30fc\u306b\u304a\u3051\u308b\u85ac\u5264\u696d\u52d9\u306e\u5c55\u958b. \u85ac\u4e8b 45, 51-56, 2003.<\/p>\n

 <\/p><\/div>\n

2002\u5e74 \u8457\u66f8\u30fb\u7dcf\u8aac<\/h4>\n
\n

1. \u5800\u7530\u5e83\u4e00\u90ce, \u7cdf\u8c37\u53f2\u4ee3, \u4e94\u5341\u5d50\u4e00\u96c4, \u6e05\u6c34\u6075\u5b50, \u677e\u539f\u548c\u592b. in vivo\u30de\u30a4\u30af\u30ed\u30c0\u30a4\u30a2\u30ea\u30b7\u30b9\u6cd5\u3092\u7528\u3044\u305f\u85ac\u6bd2\u7269\u306e\u8133\u5185\u8f38\u9001\u6e2c\u5b9a. \u6cd5\u4e2d\u6bd2, 20, 206-207, 2002.<\/p>\n

 <\/p>\n

2. \u677e\u539f\u548c\u592b. \u9662\u5185\u3067\u306e\u85ac\u5264\u5e2b\u306e\u6d3b\u52d5\u3000\u85ac\u5264\u5e2b\u696d\u52d9\u3068\u30ea\u30b9\u30af\u30de\u30cd\u30b8\u30e1\u30f3\u30c8\u3000\u5927\u5b66\u75c5\u9662\u30fb\u5730\u57df\u4e2d\u6838\u75c5\u9662\u85ac\u5264\u90e8\u306b\u304a\u3051\u308b\u53d6\u308a\u7d44\u307f. \u533b\u85ac\u30b8\u30e3\u30fc\u30ca\u30eb 38, 1783-1790, 2002.<\/p>\n

 <\/p>\n

3. \u677e\u539f\u548c\u592b. \u8133\u30fb\u795e\u7d4c\u75be\u60a3.\u3000In: \u85ac\u7269\u7642\u6cd5\uff1a\u770b\u8b77\u306e\u305f\u3081\u306e\u6700\u65b0\u533b\u5b66\u8b1b\u5ea728\u5dfb (\u5b89\u539f\u76f4\u4eba\u7de8, \u65e5\u91ce\u539f\u91cd\u660e\u30fb\u4e95\u6751\u88d5\u592b\u76e3\u4fee), pp90-108 and \u4ed8\u9332pp2-11, \u4e2d\u5c71\u66f8\u5e97, \u6771\u4eac, 2002.<\/p>\n

 <\/p><\/div>\n

2001\u5e74 \u8457\u66f8\u30fb\u7dcf\u8aac<\/h4>\n
\n

1. \u7b20\u539f\u76f4\u90a6, \u65e9\u52e2\u4f38\u6b63, \u677e\u539f\u548c\u592b. \u30b5\u30c6\u30e9\u30a4\u30c8\u30fb\u30d5\u30a1\u30fc\u30de\u30b7\u30fc\u304c\u3064\u306a\u3050\u85ac\u5264\u5e2b\u306e\u5922. \u65e5\u672c\u75c5\u9662\u85ac\u5264\u5e2b\u4f1a\u8a8c 37, 579-582, 2001.<\/p>\n

 <\/p>\n

2. \u677e\u539f\u548c\u592b, \u6e05\u6c34\u6075\u5b50. \u518d\u3073\u6ce8\u76ee\u3055\u308c\u308b\u8fb2\u85ac\u306e\u795e\u7d4c\u6bd2\u6027-\u30d1\u30e9\u30b3\u30fc\u30c8\u4e2d\u67a2\u6bd2\u6027\u767a\u73fe\u306b\u304a\u3051\u308b\u795e\u7d4c\u5316\u5b66\u7684\u6a5f\u5e8f. \u6cd5\u4e2d\u6bd2 19, 116-119, 2001.<\/p>\n

 <\/p><\/div>\n

2000\u5e74 \u8457\u66f8\u30fb\u7dcf\u8aac<\/h4>\n
\n

1. \u677e\u539f\u548c\u592b, \u9752\u5c71\u6643\u6cbb, \u677f\u57a3\u7950\u4e00, \u7c9f\u5c4b\u654f\u96c4, \u85e4\u7530\u80b2\u5fd7. \u30d1\u30fc\u30ad\u30f3\u30bd\u30f3\u75c5\u3068\u30d1\u30fc\u30ad\u30f3\u30bd\u30cb\u30ba\u30e0\uff0d\u85ac\u7269\u7642\u6cd5\u3068\u305d\u306e\u554f\u984c\u70b9\uff0d. \u5317\u6d77\u9053\u75c5\u9662\u85ac\u5264\u5e2b\u4f1a\u8a8c 69, 41-54, 2000.<\/p>\n

 <\/p>\n

2. K. Matsubara, N-Methyl-s-carbolinium neurotoxins in Parkinson\u2019s disease. In: NEROTOXINS IN PARKINSON\u2019S DISEASE. (A. Storch and M.A. Collins eds) pp131-143, Plenuum, New York 2000.<\/p>\n

 <\/p><\/div>\n

1998\u5e74 \u8457\u66f8\u30fb\u7dcf\u8aac<\/h4>\n
\n

1. \u677e\u539f\u548c\u592b, \u6e05\u6c34\u6075\u5b50, \u677f\u57a3\u7950\u4e00, \u7b20\u539f\u76f4\u90a6, \u5343\u8449\u85ab, \u5869\u91ce\u5bdb. \u30d9\u30f3\u30be\u30b8\u30a2\u30bc\u30d4\u30f3\u306b\u3088\u308b\u524d\u5411\u6027\u5065\u5fd8\u75c7\u306f\u6d77\u99ac\u30b0\u30eb\u30bf\u30df\u30f3\u9178\u4f1d\u9054\u306e\u4f4e\u4e0b\u306b\u3088\u3063\u3066\u751f\u3058\u308b. \u6700\u65b0\u533b\u5b66 53, 2123-2130, 1998.<\/p>\n

 <\/p>\n

2. \u677e\u539f \u548c\u592b. \u4ee3\u8b1d\u7684\u6d3b\u6027\u5316\u3068\u795e\u7d4c\u6bd2\u6027\uff1a\u30d1\u30fc\u30ad\u30f3\u30bd\u30f3\u75c5\u767a\u75c7\u539f\u56e0\u7269\u8cea\u306e\u63a2\u7d22. \u65e5\u6cd5\u533b\u8a8c 52, 301-305, 1998.<\/p>\n

 <\/p>\n

3. Y. Kobayashi, K. Hattori, K. Matsubara, T. Gonda, Y. Tanabe, A. Ago and H. Okunishi, \u201cEffects of chronic administration of nicotine on stress-induced changes in rats. In: Advances in Comparative Endocrinology, Proceeding of the XIIIth International Congress of Comaprative Endocrinology (eds. S. Kawashima and S. Kikuyama) pp1045-1049, Bologna, Italy, 1998.<\/p>\n

 <\/p>\n

4. M. Naoi, W. Maruyama, K. Matsubara, \u201cAnalysis of endogenous neurotoxins, salsolinol derivatives, in human materials for the study on pathogenesis of neurodegenerative disorders. In: Progress in HPLC-HPCE, Volume 7; Neurochemical Markers of Degenerative Nervous Diseases and Drug Addiction (Eds. Qureshi AG, Parvez H, Caudy P, Parvez S.), P. Parvez and P. Tipton, pp413-460, VSP, Utrecht-Tokyo,d 1998.<\/p>\n

 <\/p><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u539f\u8457\u8ad6\u6587(1998\u5e74~2012\u5e74)\u3000\u3000\u25bc 2012\u5e74 \u539f\u8457\u8ad6\u6587 1. \u5c71\u672c\u8b72, \u7c9f\u5c4b\u654f\u96c4, \u5c0f\u57ce\u9999\u7dd2\u91cc, \u68ee\u7530\u771f\u6a39\u5b50, \u5ddd\u5b88\u7530\u65e9\u7d00, \u795e\u5d0e\u90c1\u4ee3, \u5c0f\u5ddd\u8061, \u677f\u57a3\u7950\u4e00, \u5927\u6edd\u5eb7\u4e00, \u5c71\u672c\u4e45\u4ec1\u5b50, \u7530\u5d0e\u5609\u4e00, \u677e\u539f\u548c\u592b. \u85ac […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"vkexunit_cta_each_option":"","footnotes":""},"class_list":["post-3309","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.asahikawa-med.ac.jp\/hospital\/pharmacy\/wp-json\/wp\/v2\/pages\/3309","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.asahikawa-med.ac.jp\/hospital\/pharmacy\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.asahikawa-med.ac.jp\/hospital\/pharmacy\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.asahikawa-med.ac.jp\/hospital\/pharmacy\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.asahikawa-med.ac.jp\/hospital\/pharmacy\/wp-json\/wp\/v2\/comments?post=3309"}],"version-history":[{"count":12,"href":"https:\/\/www.asahikawa-med.ac.jp\/hospital\/pharmacy\/wp-json\/wp\/v2\/pages\/3309\/revisions"}],"predecessor-version":[{"id":4583,"href":"https:\/\/www.asahikawa-med.ac.jp\/hospital\/pharmacy\/wp-json\/wp\/v2\/pages\/3309\/revisions\/4583"}],"wp:attachment":[{"href":"https:\/\/www.asahikawa-med.ac.jp\/hospital\/pharmacy\/wp-json\/wp\/v2\/media?parent=3309"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}